SIX1 Reprograms Myogenic Transcription Factors to Maintain the Rhabdomyosarcoma undifferentiated state
J. Y. Hsu, E. P. Danis, S. Nance, J. O'Brien, V. M. Wessells, A. E. Goodspeed, J. C. Talbot, S. L. Amacher, P. Jedlicka, J. C. Black, J. C. Costello, A. D. Durbin, K. B. Artinger, H. L. Ford
Abstract
Rhabdomyosarcoma (RMS) is a pediatric skeletal muscle sarcoma characterized by the expression of the myogenic-lineage transcription factors (TF) MYOD1 and MYOG. Despite high expression of these TFs, RMS cells fail to terminally differentiate, suggesting the presence of factors that alter their function. Here, we demonstrate that the developmental TF, SIX1, is highly expressed in RMS and is critical to maintain a muscle progenitor-like state. SIX1 loss induces terminal differentiation of RMS cells into myotube-like cells and dramatically impedes tumor growth in vivo. We show that SIX1 maintains the RMS undifferentiated state by controlling enhancer activity and MYOD1 occupancy at loci more permissive to tumor growth over terminal muscle differentiation. Finally, we demonstrate that a gene signature derived from SIX1 loss correlates with differentiation status in RMS and predicts RMS progression in human disease. Our findings demonstrate a master regulatory role for SIX1 in the repression of RMS differentiation via genome-wide alterations in MYOD1-mediated transcription. HighlightsO_LISIX1 prevents differentiation in RMS while it promotes differentiation during normal development C_LIO_LIFN-RMS are highly dependent on SIX1 for growth in both zebrafish and mouse xenograft models C_LIO_LILoss of SIX1 alters the transcriptional landscape of RMS cells, inducing a growth to differentiation switch C_LIO_LISIX1 knockdown in FN-RMS causes reduced super enhancer-based activity at stem-related genes and enhanced MYOD1 binding to differentiation loci, resulting in the activation of a myogenic differentiation program C_LIO_LIA gene signature derived from SIX1 loss strongly correlates with myogenic differentiation status and is predictive of advanced RMS. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma
Anh Tuan Vuong, Aniket S. Joshi, … Ashok Kumar·OncogenePeer-reviewed·Apr 6, 2026
- PROX1 transcription factor is a master regulator of myogenic and oncogenic features of rhabdomyosarcoma
N. Y. Gizaw, P. Kallio, … R. Kivela·bioRxiv·Apr 19, 2020
- Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance
S. G. Danielli, E. Porpiglia, … B. W. Schäfer·bioRxiv·Apr 20, 2022
- Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma
S. G. Danielli, Y. Wei, … D. M. Langenau·bioRxiv·Oct 13, 2023
- Targeting the IRE1α-XBP1 signaling axis impairs tumor growth and promotes myogenic differentiation in rhabdomyosarcoma
Tuan Anh Vuong, Aniket S. Joshi, … Ashok Kumar·Communications BiologyPeer-reviewed·May 6, 2026
- Alterations of the TGFb-sequestration complex member ADAMTSL1 levels are associated with muscular defects and rhabdomyosarcoma aggressiveness
A. Bertrand-Chapel, S. Meyer, … M. CASTETS·bioRxiv·Mar 7, 2023